Crescent BiopharmaCBIO +9.24%10 ROA % is -42.39% as of Mar. 2026. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,422 Biotechnology companies, Crescent Biopharma ranks worse than 80.31% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Crescent Biopharma's annualizedNet Income for the quarter that ended in Mar. 2026 was $-93.13 Mil.
Crescent Biopharma's average Total Assets over the quarter that ended in Mar. 2026 was $219.71 Mil. Therefore, Crescent Biopharma's annualized ROA % for the quarter that ended in Mar. 2026 was -42.39%.
The historical rank and industry rank for Crescent Biopharma's ROA % or its related term are showing as below:
CBIO'
s ROA % Range Over the Past 10 Years
Min: -111.59 Med: -111.59 Max: -88.19
Current: -88.19
During the past 2 years, Crescent Biopharma's highest ROA % was -88.19%. The lowest was -111.59%. And the median was -111.59%.
CBIO's ROA % is ranked worse than 80.31% of 1422
companies
in the Biotechnology industry
Industry Median: -32.87
vs CBIO: -88.19
Crescent Biopharma (NAS:CBIO) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Crescent Biopharma ROA % Related Terms
Crescent Biopharma ROA % Historical Data
* Premium members only.
The historical data trend for Crescent Biopharma's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Crescent Biopharma's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescent Biopharma ROA % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crescent Biopharma's ROA % distribution charts can be found below:
* The bar in red indicates where Crescent Biopharma's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Crescent Biopharma (CBIO) has a ROA % of -42.39% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Crescent Biopharma and its competitors. According to the industry distribution chart, Crescent Biopharma ranks #1142 out of 1422 companies in the Biotechnology industry, placing it in the top 80.3%.
Is Crescent Biopharma's ROA % too high?
Crescent Biopharma's current ROA % is -42.39%. Based on the distribution chart, Crescent Biopharma ranks #1142 out of 1422 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's ROA % compare to RIGL and GYRE?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #1142 out of 1422 companies for ROA %. This places Crescent Biopharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Crescent Biopharma and its competitors. Crescent Biopharma's current ROA % is -42.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current ROA % of -42.39%. The current ROA % is -42.39%. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current ROA % is -42.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score
Get the complete analysis for CBIO
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBIO has been successfully added to your 